- Original
- Open access
- Published:
Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine
The Journal of Headache and Pain volume 8, pages 283–288 (2007)
Abstract
Acute treatment of menstrual migraine (MM) attacks is often incomplete and unsatisfactory, and perimenstrual prophylaxis with triptans, oestrogen supplementation or naproxen sodium may be needed for decreasing frequency and severity of the attack. In this pilot, open-label, non-randomised, parallel group study we evaluated, in 38 women with a history of MM, the efficacy of frovatriptan (n=14) 2.5 mg per os or transdermal oestrogens (n=10) 25 μg or naproxen sodium (n=14) 500 mg per os once-daily for the short-term prevention of MM. All treatments were administered in the morning for 6 days, beginning 2 days before the expected onset of menstrual headache. All women were asked to fill in a diary card, in the absence of (baseline) and under treatment, in order to score headache severity. All women reported at least one episode of MM at baseline. During treatment all patients taking transdermal oestrogens or naproxen sodium and 13 out of the 14 patients (93%) taking frovatriptan had at least one migraine attack (p=0.424). Daily incidence of migraine was significantly (p=0.045) lower under frovatriptan than under transdermal oestrogens or NS. At baseline, the overall median score of headache severity was 4.6, 4.2 and 4.3 in the group subsequently treated with frovatriptan, transdermal oestrogens and naproxen sodium, respectively (p=0.819). During treatment the median score was significantly lower under frovatriptan (2.5) than under transdermal oestrogens (3.0) and naproxen sodium (3.9, p=0.049). This was evident also for each single day of observation (p=0.016). Among treatments differences were particularly evident for the subgroup of patients with true MM (n=22) and for frovatriptan vs. naproxen sodium. This study suggests that short-term prophylaxis of MM with frovatriptan may be more effective than that based on transdermal oestrogens or naproxen sodium.
References
Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF (2007) AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349 10.1212/01.wnl.0000252808.97649.21, 1:STN:280:DC%2BD2s%2FlslCgsg%3D%3D, 17261680
Breslau N, Rasmussen BK (2001) The impact of migraine: Epidemiology, risk factors, and co-morbidities. Neurology 56[6 Suppl 1]:4–12
Brandes JL (2006) The influence of estrogen on migraine: a systematic review. JAMA 295:1824–1830 10.1001/jama.295.15.1824, 1:CAS:528:DC%2BD28Xjs12nt7k%3D, 16622144
Headache Classification Committee of the International Headache Society (2004) The International Classification of Headache Disorders. Cephalalgia 24[Suppl. 1]:1–160
Granella F, Sances G, Allais G, Nappi RE, Tirelli A, Benedetto C et al (2004) Characteristics of menstrual and non-menstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 24:707–716 10.1111/j.1468-2982.2004.00741.x, 1:STN:280:DC%2BD2cvntlagsA%3D%3D, 15315526
Allais G, Benedetto C (2004) Update on menstrual migraine: from clinical aspects to therapeutical strategies. Neurol Sci 25[Suppl 3]:229–231 10.1007/s10072-004-0292-6
Mannix LK (2003) Management of menstrual migraine. Neurologist 9:207–213 10.1097/01.nrl.0000080952.78533.0a, 12864931
Ashkenazi A, Silberstein SD (2006) Hormone-related headache: pathophysiology and treatment. CNS Drugs 20:125–141 10.2165/00023210-200620020-00004, 1:CAS:528:DC%2BD28XkvFGgurY%3D, 16478288
MacGregor A (2000) Migraine associated with menstruation. Funct Neurol 15[Suppl 3]:143–153 11200785
Martin V (2007) Targeted treatment strategies for menstrual migraine. J Fam Pract 56:13–22 17270114
Silberstein SD, Elkind AH, Schreiber C, Keywood C (2004) A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 63:261–269 1:CAS:528:DC%2BD2cXlsV2jt7g%3D, 15277618
Newman L, Mannix LK, Landy S, Silberstein S, Lipton RB, Putnam DG et al (2001) Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache 41:248–256 10.1046/j.1526-4610.2001.111006248.x, 1:STN:280:DC%2BD3MvotlCktw%3D%3D, 11264684
Newman LC, Lipton RB, Lay CL, Solomon S (1998) A pilot study of oral sumatriptan as intermittent prophylaxis of menstruation-related migraine. Neurology 51:307–309 1:CAS:528:DyaK1cXkvVWmt7s%3D, 9674831
Moschiano F, Allais G, Grazzi L, Usai S, Benedetto C, D’Amico D et al (2005) Naratriptan in the short-term prophylaxis of pure menstrual migraine. Neurol Sci 26[Suppl 2]:162–166 10.1007/s10072-005-0435-4
Allais G, Bussone G, De Lorenzo C, Mana O, Benedetto C (2005) Advanced strategies of short-term prophylaxis in menstrual migraine: state of the art and prospects. Neurol Sci 26[Suppl 2]:125–129 10.1007/s10072-005-0424-7
Geraud G, Spierings EL, Keywood C (2002) Tolerability and safety of frovatriptan with short-and long-term use for treatment of migraine and in comparison with sumatriptan. Headache 42[Suppl 2]:93–99 10.1046/j.1526-4610.42.s2.7.x
Belsey EM, Farley TM (1988) The analysis of menstrual bleeding patterns: a review. Contraception 38:129–156 10.1016/0010-7824(88)90035-2, 1:STN:280:DyaL1M%2FgsVSmtg%3D%3D, 3048871
Smits MG, van der Meer YG, Pfeil JP, Rijnierse JJ, Vos AJ (1994) Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 34:103–106 10.1111/j.1526-4610.1994.hed3402103.x, 1:STN:280:DyaK2c3hs1Witw%3D%3D, 8163364
Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G (1990) Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 30:705–709 10.1111/j.1526-4610.1990.hed3011705.x, 1:STN:280:DyaK3M7mtFeitQ%3D%3D, 2074162
Pradalier A, Vincent D, Beaulieu P, Baudesson G, Launay J (1994) Correlation between oestradiol plasma level and therapeutic effect on menstrual migraine. In: Rose C, ed. New Advances in Headache Research: 4. London: Smith-Gordon 129–132
Pfaffenrath VL (1993) Efficacy and safety of percutaneous estradiol vs. placebo in menstrual migraine. Cephalalgia 13[suppl]:244–247
Smits MG, van der Meer YG, Pfeil JP, Rijnierse JJ, Vos AJ (1994) Perimenstrual migraine: effect of Estraderm TTS and the value of contingent negative variation and exteroceptive temporalis muscle suppression test. Headache 34:103–106 10.1111/j.1526-4610.1994.hed3402103.x, 1:STN:280:DyaK2c3hs1Witw%3D%3D, 8163364
MacGregor EA (2004) Oestrogen and attacks of migraine with and without aura. Lancet Neurol 3:354–361 10.1016/S1474-4422(04)00768-9, 1:CAS:528:DC%2BD2cXltlCqt70%3D, 15157850
Nappi RE, Sances G, Brundu B, De Taddei S, Sommacal A, Ghiotto N et al (2005) Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod 20:3423–3428 10.1093/humrep/dei260, 1:CAS:528:DC%2BD2MXht1Gltr3N, 16123089
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License ( https://creativecommons.org/licenses/by-nc/2.0 ), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Guidotti, M., Mauri, M., Barrilà, C. et al. Frovatriptan vs. transdermal oestrogens or naproxen sodium for the prophylaxis of menstrual migraine. J Headache Pain 8, 283–288 (2007). https://doi.org/10.1007/s10194-007-0417-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10194-007-0417-4